Ascelia Pharma AB (publ) (ACE.ST)
SEK 3.09
(1.82%)
SEK 3.09
(1.82%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -109.28 Million SEK | 16.72% |
| 2022 | -131.22 Million SEK | -4.22% |
| 2021 | -125.9 Million SEK | -27.57% |
| 2020 | -98.69 Million SEK | -147.33% |
| 2019 | -39.9 Million SEK | -7.46% |
| 2018 | -37.13 Million SEK | -52.24% |
| 2017 | -24.39 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -16.69 Million SEK | -57.51% |
| 2024 Q2 | -13.27 Million SEK | 20.5% |
| 2023 Q1 | -37.21 Million SEK | 30.28% |
| 2023 Q4 | -10.59 Million SEK | 50.05% |
| 2023 FY | -109.28 Million SEK | 16.72% |
| 2023 Q2 | -40.25 Million SEK | -8.15% |
| 2023 Q3 | -21.21 Million SEK | 47.28% |
| 2022 Q2 | -22.8 Million SEK | 21.56% |
| 2022 Q1 | -29.07 Million SEK | 17.1% |
| 2022 FY | -131.22 Million SEK | -4.22% |
| 2022 Q3 | -25.95 Million SEK | -13.82% |
| 2022 Q4 | -53.38 Million SEK | -105.64% |
| 2021 Q1 | -28.81 Million SEK | 19.62% |
| 2021 FY | -125.9 Million SEK | -27.57% |
| 2021 Q2 | -33.49 Million SEK | -16.24% |
| 2021 Q3 | -28.52 Million SEK | 14.85% |
| 2021 Q4 | -35.07 Million SEK | -22.97% |
| 2020 FY | -98.69 Million SEK | -147.33% |
| 2020 Q2 | -31.44 Million SEK | -88.13% |
| 2020 Q4 | -35.85 Million SEK | -144.04% |
| 2020 Q3 | -14.69 Million SEK | 53.28% |
| 2020 Q1 | -16.71 Million SEK | 38.41% |
| 2019 Q2 | -14.52 Million SEK | -25.18% |
| 2019 Q1 | -11.6 Million SEK | -61.99% |
| 2019 FY | -39.9 Million SEK | -7.46% |
| 2019 Q4 | -27.13 Million SEK | -112.47% |
| 2019 Q3 | -12.77 Million SEK | 12.09% |
| 2018 Q1 | -4.41 Million SEK | 52.6% |
| 2018 FY | -37.13 Million SEK | -52.24% |
| 2018 Q2 | -7.87 Million SEK | -78.56% |
| 2018 Q3 | -3.83 Million SEK | 51.27% |
| 2018 Q4 | -7.16 Million SEK | -86.61% |
| 2017 FY | -24.39 Million SEK | 0.0% |
| 2017 Q4 | -9.3 Million SEK | -53.83% |
| 2017 Q3 | -6.05 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -12.82 Million SEK | -751.949% |
| BioArctic AB (publ) | 229.24 Million SEK | 147.672% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -510.65% |
| CombiGene AB (publ) | -35.66 Million SEK | -206.426% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 28.029% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -566.472% |
| OncoZenge AB (publ) | -15.9 Million SEK | -587.259% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 56.036% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 76.557% |
| Mendus AB (publ) | -101.61 Million SEK | -7.547% |
| LIDDS AB (publ) | -40.2 Million SEK | -171.82% |
| Lipum AB (publ) | -37.17 Million SEK | -193.959% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 998.085% |
| Simris Alg AB (publ) | -37.3 Million SEK | -192.958% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -158.835% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -360.412% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 71.845% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 39.172% |
| Ziccum AB (publ) | -21.41 Million SEK | -410.405% |
| AcouSort AB (publ) | -17.08 Million SEK | -539.522% |
| Active Biotech AB (publ) | -45.8 Million SEK | -138.62% |
| Alzinova AB (publ) | -16.48 Million SEK | -563.155% |
| Amniotics AB (publ) | -30.87 Million SEK | -254.027% |
| Camurus AB (publ) | 431.44 Million SEK | 125.331% |
| Cantargia AB (publ) | -280.02 Million SEK | 60.972% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -418.174% |
| Genovis AB (publ.) | 61.5 Million SEK | 277.704% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 3.561% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -194.807% |
| Intervacc AB (publ) | -102.85 Million SEK | -6.258% |
| Kancera AB (publ) | -64.88 Million SEK | -68.423% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 2129.113% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -801.121% |
| NextCell Pharma AB | -41.95 Million SEK | -160.459% |
| Saniona AB (publ) | -95.81 Million SEK | -14.067% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 64.853% |
| Xintela AB (publ) | -54.08 Million SEK | -102.075% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -24851.598% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -561.43% |
| Corline Biomedical AB | -1.8 Million SEK | -5941.349% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 38.547% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -92.337% |
| Aptahem AB (publ) | -11.11 Million SEK | -883.436% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 11.197% |
| Fluicell AB (publ) | -26.55 Million SEK | -311.569% |
| Biovica International AB (publ) | -124.82 Million SEK | 12.446% |
| Abliva AB (publ) | -95.5 Million SEK | -14.427% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 66.568% |
| 2cureX AB (publ) | -32.51 Million SEK | -236.085% |
| I-Tech AB | 20.2 Million SEK | 640.949% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 86.86% |
| Cyxone AB (publ) | -22.98 Million SEK | -375.393% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -19.57% |
| Biosergen AB | -27.03 Million SEK | -304.216% |
| Nanologica AB (publ) | -75.15 Million SEK | -45.413% |
| SynAct Pharma AB | -215.81 Million SEK | 49.359% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -148.077% |
| BioInvent International AB (publ) | -330.3 Million SEK | 66.913% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 56.129% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -1000.583% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -835.845% |